BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

  October 1, 2026

   · 

  8 min read
• Press Releases

  Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

  October 1, 2026

   · 

  9 min read
• Press Releases

  Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial

  October 1, 2026

   · 

  6 min read
• Press Releases

  Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

  October 1, 2026

   · 

  8 min read
• Press Releases

  Pfizer’s Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

  October 1, 2026

   · 

  10 min read
• Press Releases

  EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

  October 1, 2026

   · 

  8 min read
• Press Releases

  Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline

  October 1, 2026

   · 

  3 min read
• Press Releases

  Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition

  October 1, 2026

   · 

  4 min read
• Press Releases

  Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

  October 1, 2026

   · 

  16 min read
• Press Releases

  Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

  October 1, 2026

   · 

  21 min read